These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Luteolin inhibits adipogenic differentiation by regulating PPARgamma activation.
    Author: Park HS, Kim SH, Kim YS, Ryu SY, Hwang JT, Yang HJ, Kim GH, Kwon DY, Kim MS.
    Journal: Biofactors; 2009; 35(4):373-9. PubMed ID: 19353690.
    Abstract:
    Luteolin (3',4',5,7-tetrahydroxyflavone), a flavonoid, has been known to possess antimutagenic, antitumorigenic, antioxidant, and anti-inflammatory properties. In this study, we investigated the role of luteolin in the regulation of adipogenic differentiation in 3T3-L1 preadipocytes. Luteolin inhibited intracellular triglyceride accumulation in a dose-dependent manner without cytotoxicity. Western blot and reverse transcription-polymerase chain reaction analyses showed that this inhibition was accompanied by attenuated expression of the adipogenic transcription factors: peroxisome proliferator-activated receptor gamma (PPARgamma) and CCAAT/enhancer-binding protein alpha. Luteolin inhibited the PPARgamma transactivation stimulated by rosiglitazone, a synthetic agonist, in COS-7 cells and inhibited rosiglitazone-induced adipogenic differentiation in 3T3-L1 cells. These data suggest that luteolin exerts antiadipogenic effects by suppressing adipogenic transcription factors and by inhibiting the transactivation of PPARgamma.
    [Abstract] [Full Text] [Related] [New Search]